GET DAILY SIGNALSWhy Is UFP Technologies (UFPT) Stock Down -1.60% Today?
Key Takeaways
- UFPT shares slipped about 1.60% to $313.77 in early trading on Tuesday, November 10, 2026, retreating from the prior session's close of $318.86.
- The decline reflects profit-taking and consolidation after a sharp post-earnings rally driven by better-than-expected third-quarter results.
- A secondary headwind came from management's own comments that the fourth quarter is seasonally softer, partly due to planned holiday production shutdowns in the Dominican Republic.
- Broader context: the pullback follows a 5.07% gain in the previous session and a 52-week high near $342 touched shortly after the earnings release.
- Traders are watching whether the stock can hold its post-earnings gains, along with upcoming fourth-quarter results and progress on the company's acquisition pipeline.
- For deeper analysis, explore the Price Targets, Earnings, and Forecast pages.
- To see how AI-driven strategies are trading this and other tickers, visit the Trending AI Robots page.
Opening Summary
UFP Technologies, Inc. (UFPT), a Newburyport, Massachusetts-based contract development and manufacturing organization (CDMO) serving the medical device, sterile packaging, and engineered custom products markets, traded lower in early Tuesday's session. The stock was down about 1.60% to $313.77, compared with a prior close of $318.86, marking a modest step back after a multi-day, earnings-driven advance. Markets attributed the move primarily to profit-taking and consolidation following last week's strong third-quarter results, with investors weighing management's cautious seasonal outlook for the current quarter.
Post-Earnings Consolidation and Profit-Taking
The dominant force behind Tuesday's decline appears to be routine profit-taking. Shares of UFPT surged roughly 17% on November 4 after the company reported third-quarter adjusted earnings per share of $2.88, comfortably above analyst estimates near $2.49 to $2.63, on revenue of $172.4 million that also topped consensus. Gross margin expanded to 29.4% from 27.7% a year earlier, and MedTech sales grew 12.5%.
That earnings-driven rally pushed the stock to a 52-week high around $342.11 before momentum cooled. After the following session's sharp pullback and a subsequent recovery that carried shares to a 5.07% gain on Monday, the stock opened Tuesday in profit-taking territory, a common pattern as short-term traders lock in gains from a strong run rather than a signal of deteriorating fundamentals.
Seasonal Guidance Weighs on Sentiment
Investors are also digesting management's forward-looking commentary. On the company's earnings call, executives reiterated their long-term growth framework of 12% to 18% total growth but cautioned that the fourth quarter is traditionally softer, in part because of planned holiday production shutdowns in the Dominican Republic as more activity shifts to that location. The company also noted that its AJR program transfers and related margin improvements remain behind schedule, with completion now expected into 2027.
That softer near-term tone has tempered enthusiasm even as the company highlighted an active acquisition pipeline, plans to expand its credit facility, and investments in additional capacity at DAS Medical to support double-digit growth.
Market Context and Trading Activity
The move in UFPT on Tuesday appeared relatively muted on the volume front in early trading, contrasting with the elevated turnover seen around the earnings release, when roughly 195,000 shares changed hands versus a typical daily average nearer 116,000. The decline also unfolded against a backdrop of choppy trading in healthcare and medical device names, with small- and mid-cap medtech stocks showing uneven price action after a strong prior week.
Technically, the stock continues to trade well above its pre-earnings levels, holding the bulk of its post-report gains despite Tuesday's dip. The $300 to $303 zone, which acted as support in the days immediately following earnings, remains a key level for traders monitoring whether the pullback extends or stabilizes.
What Comes Next for UFPT
Looking ahead, investors will be focused on whether UFPT can sustain its organic growth momentum into a seasonally softer fourth quarter and deliver on its multi-year expansion plans into 2027. Key watch items include the company's next earnings report, expected around late February 2027, any developments on its acquisition pipeline and credit facility expansion, and the pace of program transfers in the Dominican Republic.
Risks include the potential for margin pressure from ongoing AJR inefficiencies, higher SG&A spending as the company invests ahead of growth, and broader volatility in healthcare and medtech equities. Conversely, continued double-digit organic growth and successful acquisition execution could reinforce the bullish thesis that has supported the stock's strong year-to-date performance.
Trending AI Robots
Tickeron offers hundreds of AI trading bots covering thousands of tickers, each built around distinct strategies, timeframes, performance metrics, and traded symbols. The Trending AI Robots section curates only the strongest performers under current market conditions, giving traders a focused view of which automated strategies are excelling right now. Explore the page to see how AI-driven approaches are navigating names like UFPT and the broader market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
UFPT in upward trend: price rose above 50-day moving average on November 04, 2026
UFPT moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend. In 35 of 41 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 59 cases where UFPT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on UFPT as a result. In 74 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for UFPT just turned positive on November 04, 2026. Looking at past instances where UFPT's MACD turned positive, the stock continued to rise in 43 of 53 cases over the following month. The odds of a continued upward trend are 81%.
The 10-day moving average for UFPT crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.
Following a +6.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where UFPT advanced for three days, in 275 of 337 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The 10-day RSI Indicator for UFPT moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 45 similar instances where the indicator moved out of overbought territory. In 30 of the 45 cases, the stock moved lower in the following days. This puts the odds of a move lower at 67%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UFPT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.
UFPT broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for UFPT entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 30 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. UFPT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 52 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.083) is normal, around the industry mean (4.142). P/E Ratio (32.387) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (5.110) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.449) is also within normal values, averaging (40.124).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company that engages in designing custom converting of foams, plastics, composites and natural fiber materials
Industry MedicalNursingServices
Advertisement